Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.87 USD

28.87
12,948,956

-0.22 (-0.76%)

Updated Sep 30, 2024 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PWV

Pfizer's (PFE) COVID-19 Drug Paxlovid Gets FDA Panel Vote

by Zacks Equity Research

FDA's Antimicrobial Drugs Advisory Committee (AMDAC) votes 16 to 1 for Pfizer's Paxlovid for the treatment of mild-to-moderate COVID-19 in adult patients at high risk of hospitalization or death.

Kinjel Shah headshot

Pharma Stock Roundup: M&A Boom in Drug Industry With PFE & SNY Deals, Other Updates

by Kinjel Shah

Pfizer (PFE) is set to buy Seagen (SGEN) for $43 billion while Sanofi (SNY) is acquiring Provention Bio. Novo Nordisk (NVO) and Sanofi are looking to cut insulin prices.

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHD

Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.

Company News for Mar 15, 2023

by Zacks Equity Research

Companies In The News Are: META, BG, SBNY, PFE, UAL.

Pfizer (PFE) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $39.90, moving +0.1% from the previous trading session.

Shaun Pruitt headshot

Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition

by Shaun Pruitt

Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.

Pfizer (PFE) to Buy Seagen for $43B, Boost Cancer Portfolio

by Zacks Equity Research

Pfizer (PFE) is set to buy Seagen (SGEN) in a $43 billion deal. Seagen's key products focus on cancer treatment.

Company News for Mar 14, 2023

by Zacks Equity Research

Companies In The News Are: SGEN, PFE, PODD, SIVB, ILMN, PNC.

Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up

by Zacks Equity Research

Seagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news.

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Strength Seen in Seattle Genetics (SGEN): Can Its 14.5% Jump Turn into More Strength?

by Zacks Equity Research

Seattle Genetics (SGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Ethan Feller headshot

Week Ahead: Banking Crisis, Inflation Reports, and Big Pharma Acquisitions

by Ethan Feller

Last week ended on a hectic note...

Pfizer (PFE) Gets FDA Nod for Migraine Nasal Spray Zavzpret

by Zacks Equity Research

Zavzpret (zavegepant) is now part of Pfizer's (PFE) migraine drugs portfolio with the 2022 acquisition of Biohaven. Zavzpret provides migraine patients access to a fast-acting pain-relief option.

BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

BioNTech's (BNTX) fourth-quarter COVID-19 vaccine sales are likely to have declined with the pandemic largely in control. Updates on the company's booster dose authorization status and pipeline will be in focus.

Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DHS

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $40.12, moving -0.55% from the previous trading session.

Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day.

Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer

by Zacks Equity Research

Eli Lilly (LLY) announces FDA approval of label expansion of Verzenio (abemaciclib), in combination with endocrine therapy, for treating HR+, HER2-, node-positive and high-risk early breast cancer.

Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?

by Zacks Equity Research

An FDA advisory committee recommended approving Pfizer's (PFE) and GSK's respective RSV vaccines for older adults. Currently, there are no RSV vaccines anywhere in the world.

Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for DHS

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

by Zacks Equity Research

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Why Is Pfizer (PFE) Down 8.6% Since Last Earnings Report?

by Zacks Equity Research

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Company News for Feb 28, 2023

by Zacks Equity Research

Companies in The News Are: UNP, TSLA, SGEN, PFE, NFLX